New hope for heart bypass patients: drug targets dangerous low blood pressure

NCT ID NCT07671365

Not yet recruiting Disease control Sponsor: Methodist Healthcare System of San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called Angiotensin II for patients who develop dangerously low blood pressure after heart bypass surgery. About 329 adults will receive the drug along with standard treatments, and their outcomes will be compared to similar patients from the past. The goal is to see if the drug helps more people survive and recover faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Angiotensin II (Giapreza)
What this could lead to: If successful, this could provide a standard treatment for dangerous low blood pressure after heart bypass surgery, potentially saving lives and reducing time in the hospital.
What could go wrong: This is a single-center trial comparing results to past patients, not a randomized controlled study, so results may be less reliable. The drug may not improve survival or could cause side effects like excessive blood pressure or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palsy Vasoplegia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOPULMONARY BYPASS VASOPLEGIA VASOPLEGIC SHOCK

More trials for these conditions

Other studies related to the condition(s) this trial covers.